RxDoctor Payments DataLook up a doctor →

Philip Koi, MD

Urology · Silver Spring, MDNPI 1740324912

Payments from drug & device makers

$13,930in general payments, 2019–2025

Across 475 payments — averaging $29.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$2K
  • Astellas Pharma US Inc$1K
  • Medtronic$1K
  • Boston Scientific$1K
  • Johnson & Johnson$1K
  • Pfizer$758
  • plus $7K from 43 others

What the payments were for

  • Consulting fees$7505%
  • Travel & lodging$8976%
  • Food & beverage$12,03886%
  • Education$2452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,930 in reported general payments places this provider in the 75th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$313,242
Medicare patients
704
Services billed
4,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix26$75,322
MyrbetriqMirabegron56$64,654
GemtesaVibegron20$26,364
Tamsulosin Hcl422$7,495
Solifenacin Succinate76$4,324
Tolterodine Tartrate ErTolterodine Tartrate28$2,864
Finasteride178$2,799
Alfuzosin Hcl ErAlfuzosin Hcl87$2,333
Fesoterodine Fumarate ErFesoterodine Fumarate15$1,924
Trospium Chloride23$1,879
Methenamine Hippurate19$1,238
Silodosin16$1,135
Cefdinir51$980
Desmopressin Acetate11$961
NitrofurantoinNitrofurantoin Macrocrystal53$809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$651$101,68646 claims
Astellas Pharma US IncMyrbetriq$1,207$64,65456 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 274 urology providers in Maryland.

Other urology in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →